1.Асеева ЕА, Соловьев СК, Попкова ТВ и др. Ведение пациентов системной красной волчанкой в реальной клинической практике. //Научно-практическая ревматология. -2019;-No57 (2)-С.191-62.Насонов ЕЛ, редактор. Системная красная волчанка. //В кн.: Российские клинические рекомендации. Москва: ГЭОТАРМедиа; -2017. -С 113-41.3.Domer Т, Lipsky РЕ Beyond pan-B-cell-directed therapy -new avenues and insights into the pathogenesis of SLE.// Nat Rev Rheumatol. 2016;12:645-57. doi: 10.1038/nr-rheum.2016.1584.Guillot M, Rafat C. Buob D, et aL Eculizumab for catastrophic antiphospholipid syndrome -a case report and literature review.// Rheumatology (Oxford).-2018;57(11):2055-7. doi: 10.1093/rheumatology/key2285.Isenberg DA. Merrill JT. Why, why, why de-lupus (does so badly in clinical trials).// Expert Rev Clin Immunol. 2016;2:95-8. doi: 10.1586/1744666X.2016.11122706.Kaul A, Gordon C. Crow MK, et a). Systemic lupus erythematosus.// Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/ nrdp.2016.397.Lightstone L, Doria A, Wilson H. et al. Can we manage lupus nephritis without chronic corticosteroids administration? Independent association of glucocorticoids with damage accrual in SLE.//Autoimmun Rev. 2018;17(l):4-10. doi: 10.1016/j. autrev.2017.11.002 Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039. doi: 10.1038/nrdp.2016.39.8.Little J, Parker B, Lunt M. et aL Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort.// Rheumatology. 2018;57:677-87. doi: 10.1093/rheumatology/ kex4449.Pisetsky DS. Bossuyt X, Meroni PL ANA as an entry criterion for the classification of SLE. // Autoimmun Rev. 2019 Oct 19:102400. doi: 10.1016/j.autrev.2019.10240010.Ruiz-Limon P. Barbarroja N. Perez-Sanchez C, et aL Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. // Ann Rheum Dis. 2015;74(7):1450-8. doi: 10.1136/annrheum-dis-2013-20435111.Tsokos GC, Lo MS, Costa Reis P. Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. I/ Nat Rev Rheumatol. 2016; 12( 12):716-30. doi: 10.1038/ nrrheum.2016.18612.Chang HD, Tokoyoda K. Hoyer B, et aL Pathogenic memory plasma cells in autoimmunity. // Curr Opin Immunol. 2019;61:86-91. doi: 10.1016/j.coi.2019.09.00513.Little J, Parker B, Lunt M. et aL Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort.// Rheumatology. 2018;57:677-87. doi: 10.1093/rheumatology/ kex44414.Pisetsky DS. Bossuyt X, Meroni PL ANA as an entry criterion for the classification of SLE. // Autoimmun Rev. 2019 Oct 19:102400. doi: 10.1016/j.autrev.2019.10240015.Ruiz-Limon P. Barbarroja N. Perez-Sanchez C, et aL Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. // Ann Rheum Dis. 2015;74(7):1450-8. doi: 10.1136/annrheum-dis-2013-20435116.Tsokos GC, Lo MS, Costa Reis P. Sullivan KE. New insightsinto the immunopathogenesis of systemic lupus erythematosus. I/ Nat Rev Rheumatol. 2016; 12( 12):716-30. doi: 10.1038/ nrrheum.2016.18617.Chang HD, Tokoyoda K. Hoyer B, et aL Pathogenic memory plasma cells in autoimmunity. // Curr Opin Immunol. 2019;61:86-91. doi: 10.1016/j.coi.2019.09.00518.Chang HD, Tokoyoda K. Hoyer B, et aL Pathogenic memory plasma cells in autoimmunity. // Curr Opin Immunol. 2019;61:86-91. doi: 10.1016/j.coi.2019.09.00519.Little J, Parker B, Lunt M. et aL Glucocorticoid use and factors associated with variability in this use in the systemic lupus international collaborating clinics inception cohort.// Rheumatology. 2018;57:677-87. doi: 10.1093/rheumatology/ kex44420.Pisetsky DS. Bossuyt X, Meroni PL ANA as an entry criterion for the classification of SLE. // Autoimmun Rev. 2019 Oct 19:102400. doi: 10.1016/j.autrev.2019.102400